Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameBoan Biotech
Stock Code06955
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities一家綜合性生物製藥公司,致力於在中國及海外開發、製造及商業化不同治療領域的優質生物製品,專注於腫瘤、代謝、自身免疫及眼科等治療領域的生物類似藥及創新抗體藥物。
Listing Date2022-12-30
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)山東省煙台市高新技術產業開發區科技大道39號
Business Address (Hong Kong)香港九龍觀塘道348號宏利廣場5樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteboan-bio.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 19.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 3,960
Par ValueRMB 1.0 / shares
Offer Period2022-12-19 to 2022-12-22
Global Offering Shares10,694,800 shares
HK Public Offer Shares (Initial)1,069,600 shares (10.0%)
Public Offer Lots (Initial)5,348lots (Pool A2,674lots,Pool B2,674lots)
International Placing Shares (Initial)9,625,200 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share71.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 211,757,040

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 3,960
2 lots 400 HK$ 7,920
3 lots 600 HK$ 11,880
4 lots 800 HK$ 15,840
5 lots 1,000 HK$ 19,800
6 lots 1,200 HK$ 23,760
7 lots 1,400 HK$ 27,720
8 lots 1,600 HK$ 31,680
9 lots 1,800 HK$ 35,640
10 lots 2,000 HK$ 39,600
15 lots 3,000 HK$ 59,400
20 lots 4,000 HK$ 79,200
25 lots 5,000 HK$ 99,000
30 lots 6,000 HK$ 118,800
35 lots 7,000 HK$ 138,600
40 lots 8,000 HK$ 158,400
45 lots 9,000 HK$ 178,200
50 lots 10,000 HK$ 198,000
100 lots 20,000 HK$ 396,000
150 lots 30,000 HK$ 594,000
200 lots 40,000 HK$ 792,000
250 lots 50,000 HK$ 990,000
400 lots 80,000 HK$ 1,584,000
924 lots 184,950 HK$ 3,662,010
1,250 lots 250,000 HK$ 4,950,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,500 lots 300,000 HK$ 5,940,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 3.19B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +205%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣225.4百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20202021
Revenue 0158,704
Cost of sales 0-52,190
Gross profit 0106,514
Other income and gains, net 12,07313,365
Selling and distribution expenses 0-54,048
Administrative expenses -4,464-42,165
Net finance costs -11,819-11,599
Profit before tax -240,538-225,417
Income tax expense 00
Profit for the year -240,538-225,417
Profit attributable to owners -240,538-225,417
Balance Sheet
Item 202020212022-06
Cash and cash equivalents 3,629531,703
Trade and bills receivables 700107,267
Inventories 19,67298,840
Total current assets 92,062939,850
Total assets 908,0302,106,604
Total current liabilities 396,177260,482
Total liabilities 426,441554,917
Total equity 481,5891,551,687
Equity attributable to owners 481,5891,551,687
Interest-bearing borrowings 0250,000251,680
Cash Flow Statement
Item 202020212022-06
Net cash from operating activities -506,720-246,278
Net cash from investing activities -18,787-432,296
Depreciation of PP&E 10,48030,89523,260
Depreciation of right-of-use assets 2,7798,0804,667
Amortisation of intangible assets 2,62311,0348,181
Purchase of PP&E -25,053-107,729-39,116
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 19.8
First Day OpenHK$ 19.9
First Day Change-69.80%
First Day Volume1934930.0
First Day Turnover38589400.0
Use of Proceeds
1、約59.5%或91.0百萬港元將用于核心產品的研發; 2、約31.4%或48.0百萬港元將用于我們管線中其他產品的研發; 3、約6.1%或9.3百萬港元將用于商業化目的; 4、約3.0%或4.6百萬港元將用于營運資金及其他一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
UBS Securities Hong Kong Limited CE BIN466 SDIC SECURITIES CORPORATE FINANCE (HONG KONG) LIMITED CE AVL376
Overall Coordinators (2)
UBS Securities Hong Kong Limited CE BIN466 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
Joint Bookrunners (2)
UBS Securities Hong Kong Limited CE BIN466 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685
Joint Lead Managers (5)
UBS Securities Hong Kong Limited CE BIN466 SDIC SECURITIES (HONG KONG) LIMITED CE AUW685 富途证券国际(香港)有限公司 CE AZT137 Livermore Holdings Limited CE BJN764 SILVERBRICKS SECURITIES COMPANY LIMITED CE BLN458

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Harvest International Premium Value (Secondary Market) Fund SPC 99,997,920 HKD — 47.22% — 6 months 2023-06-30
2 傅和亮 23,118,480 HKD — 10.92% — 6 months 2023-06-30
3 中国生物制药有限公司 27,244,800 HKD — 12.87% — 6 months 2023-06-30

Directors & Management

PositionChinese nameEnglish Name
Chairman姜華—
Company Secretary黎少娟—
No director data available.

Major Shareholders

Major Shareholders & Holdings山東綠葉制藥有限公司(70.81%)
About this page

This page shows Boan Biotech (06955) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect